ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Division of Cancer Treatment, said that over the past decade, NCI's drug discovery and development programs have produced seven new drugs currently being used to treat cancer and AIDS. The program cost about $1.4 billion: $200 million for every New Drug Application filed.
ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Divisionof Cancer Treatment, said that over the past decade, NCI's drugdiscovery and development programs have produced seven new drugscurrently being used to treat cancer and AIDS. The program costabout $1.4 billion: $200 million for every New Drug Applicationfiled.
Dr. Chabner made the report to the National Cancer Advisory Board'sAd Hoc Working Group on NCI Intramural Programs. He added thatduring the decade, increases in AIDS research funding has hada significant effect on the intramural research program. "Intramuralscientists have shifted the focus of their research to followthe money," he said.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.